Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Mylan Inc. : Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/23/2013 | 05:05pm CEST

JOHANNESBURG and PITTSBURGH, Feb. 23, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral (ARV) products. South Africa has the world's largest HIV/AIDS population, with approximately 5.6 million(1) people living with the disease and an estimated 1.7 million(2) people receiving treatment.

Mylan's South African ARV portfolio initially will consist of 11 first- and second-line adult and pediatric regimens. Included are several innovative products, such as fixed-dose combinations, single blister "co-packs," heat-stable products and novel pediatric formulations that have been approved by the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO).

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people with access to high quality medicine. Recently, Mylan was awarded a 19% share of the ARV tender conducted by the South African government and we already have begun to deliver on this commitment. Building on this, today we are pleased to launch a broad and innovative ARV portfolio for the private sector. We believe that Mylan can set a new standard in the treatment of HIV/AIDS in South Africa by providing health care providers and those living with the disease access to high quality, affordable medicines."

Paul Miller, managing director and vice president of Mylan's South African business noted, "Mylan is an established leader in ARVs, with a global portfolio of 43 high quality ARVs, and the company has played a significant role in reducing the cost of these important therapies. The launch of Mylan's ARV portfolio in South Africa builds on our existing commercial presence in the country and is consistent with the company's commitment to addressing unmet needs with quality products. Mylan's ARV medicines are produced according to current Good Manufacturing Practices at facilities that have been inspected by leading regulatory authorities, including the South African Medicines Control Council, FDA and WHO. These quality standards are paramount everywhere that Mylan operates, including in South Africa."

Mylan has been a leading global player in the ARV arena for more than a decade. In 2002, Mylan Laboratories Limited (formerly Matrix Laboratories Limited) began providing reliable supplies of ARV active pharmaceutical ingredients to generic drug makers. In 2007, the company began offering finished dosage forms and launched a line of pediatric ARVs. Today, Mylan is widely respected for the quality, dependability and affordability of its ARVs. Mylan supplies ARVs to more than 120 countries around the world and nearly 40% of HIV/AIDS patients receiving treatment in developing countries depend on one of the company's ARV products.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which more than one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

[1] http://www.unaids.org/en/regionscountries/countries/southafrica/

[2] http://www.unaids.org/en/regionscountries/countries/southafrica/

SOURCE Mylan Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
05/23 MYLAN : Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefe..
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
05/17 MYLAN : Theravance Biopharma and Mylan to Present Additional Data for Revefenaci..
05/16 MYLAN : to Present at UBS Global Healthcare Conference
05/16 MYLAN : Honors National Women's Health Week to Empower Women to Take Control of ..
05/11 GSK escapes Advair hit for now as second generic bid fails
05/10DJMARKET SNAPSHOT : Nasdaq Closes At Record For 4th Straight Day As Dow Slips In F..
05/10DJMARKET SNAPSHOT : Stock Market Flat As Investors Digest Trump's Firing Of FBI's ..
05/10 Mylan says disagrees with FDA over generic Advair delay
05/10DJMARKET SNAPSHOT : Stock Market Falls After Trump's Firing Of FBI's Comey Raises ..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close